NCT07122609View on ClinicalTrials.gov

Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

August 5, 2025

Primary Completion Date

August 15, 2026

Study Completion Date

August 15, 2027

Conditions
Relapsed and Refractory DLBCL
Interventions
DRUG

Pirtobrutinib

Dose:200mg，d1-21

DRUG

R-GemOx

Dose: Rituximab: 375mg/m2, d1; Gemcitabine: 1000mg/m2, d2; Oxaliplatin:100mg/m2, d2

DRUG

Polatuzumab Vedotin

Dose: 1.8mg/kg，iv，d1 (For patient who is CD79b positive and has not previously received polatuzumab Vedotin)

Trial Locations (1)

200025

Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai

All Listed Sponsors
lead

Ruijin Hospital

OTHER